← Eichor
Condition: Metastatic Ovarian Carcinoma Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Metastatic Ovarian Carcinoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Study of SYN818 With Olaparib for the Treatment of Locally Advanced or Metastatic Solid Tumors
Phase 1 · 2 location(s) · Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd · NCT07156253Secondary Interval Cytoreductive Surgery in Platinum-sensitive Recurrent Epithelial Ovarian Cancer
NA · 1 location(s) · The University of Hong Kong · NCT06292286Immunotherapy-related CRP Kinetics in Metastatic Gynecological Malignancies
Phase N/A · 1 location(s) · University Hospital Tuebingen · NCT05914974Study of SYN818 for the Treatment of Advanced or Metastatic Solid Tumors
Phase 1 · 2 location(s) · Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd · NCT06666270A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Gynecologic Cancer
Phase 1 · 1 location(s) · Chongqing Precision Biotech Co., Ltd · NCT06215950This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Tor
Phase 1 · 3 location(s) · Zumutor Biologics Inc. · NCT06451497Secondary Cytoreduction Followed by Chemotherapy Versus Chemotherapy Alone in Relapsed Ovarian Cancer After PARPi Mainte
NA · 1 location(s) · Women's Hospital School Of Medicine Zhejiang University · NCT05607329Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Per
Phase 1 · 1 location(s) · National Cancer Institute (NCI) · NCT04847063WellSpan-THRIVE Cancer QOL Study
Phase N/A · 5 location(s) · WellSpan Health · NCT07433660A Study of MGC026 in Participants With Advanced Solid Tumors
Phase 1 · 12 location(s) · MacroGenics · NCT06242470Measuring Oncological Value of Exercise and Statin
Phase 3 · 1 location(s) · Tampere University Hospital · NCT05796973Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanc
Phase 1 · 12 location(s) · Whitehawk Therapeutics, Inc. · NCT07444814Evaluating Efficacy and Tolerability of Anticancer Drug Therapies for the Treatment of Gynecologic and Breast Cancers
Phase N/A · 1 location(s) · IRCCS Azienda Ospedaliero-Universitaria di Bologna · NCT06800612Genetic Landscape in Women with Metastatic Ovarian Cancer Before and During Treatment with PARP Inhibitors
NA · 1 location(s) · European Institute of Oncology · NCT06785077Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Phase 1 · 10 location(s) · Nammi Therapeutics Inc · NCT06582017Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in
Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT03412877CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With
Phase 2 · 1 location(s) · Northwestern University · NCT05733000Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07523529Access to Genetic Testing in Underserved Patients With Cancer
NA · 2 location(s) · University of Southern California · NCT06422455HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer
Phase 2 · 28 location(s) · Hansoh BioMedical R&D Company · NCT06014190A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
Phase 1 · 9 location(s) · Normunity AccelCo, Inc. · NCT07182149A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patien
Phase 1/Phase 2 · 1 location(s) · Shenzhen Ionova Life Sciences Co., Ltd. · NCT07610798Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Phase 1/Phase 2 · 66 location(s) · Genmab · NCT05579366Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C M
Phase 1/Phase 2 · 53 location(s) · Revolution Medicines, Inc. · NCT06128551SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Phase N/A · 68 location(s) · Massive Bio, Inc. · NCT03452774Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel i
Phase 1 · 1 location(s) · M.D. Anderson Cancer Center · NCT05092373Autologous and Allogeneic Whole Cell Cancer Vaccine for Metastatic Tumors
Phase 1/Phase 2 · 1 location(s) · Hadassah Medical Organization · NCT00722228Personalized Patient Derived Xenograft (pPDX) Modeling to Test Drug Response in Matching Host
Phase N/A · 1 location(s) · University Health Network, Toronto · NCT02732860Secondary Cytoreductive Surgery After Chemotherapy for Recurrent Epithelial Ovarian Cancer
Phase 2 · 1 location(s) · National Cancer Center, Korea · NCT07171528First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Incl
Phase 1 · 6 location(s) · Accent Therapeutics · NCT06799065
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.